Brief: Helix Biopharma Commences L-Dos47 Phase Lb/Ll Pancreatic Cancer Clinical Study
11/12/2019 23:57
Dec 11 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. COMMENCES L-DOS47 PHASE LB/LL
PANCREATIC
CANCER CLINICAL STUDY
Source text for Eikon: ID:nGNX5pzZ3F
Further company coverage: HBP.TO
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020